PT-141 – 10mg

PT-141, also known as bremelanotide, is a peptide and a tanning melanocortin receptor agonist primarily targeting MC4R, which plays a crucial role in enhancing sexual desire and arousal in both men and women. This compound has gained notable recognition through studies such as “PT-141: a melanocortin agonist for the treatment of sexual dysfunction” and “Salvage of sildenafil failures with bremelanotide,” underscoring its potential in addressing sexual dysfunctions.

Originally identified from research on α-MSH, a hormone involved in skin pigmentation and sexual behavior, PT-141 evolved as a synthetic derivative aimed at sexual function enhancement. Approved in 2019 by the FDA for treating hypoactive sexual desire disorder (HSDD) in premenopausal women, it’s commercially available under the brand Vyleesi. Palatin Technologies, the developer, markets this drug in auto-injection pens.

​PT-141 is specifically developed by modifying the structure of Melanotan II to enhance its efficacy in treating sexual dysfunction. This modification focuses on its ability to selectively activate certain melanocortin receptors in the body, particularly MC4R, which is involved in sexual arousal. Unlike Melanotan II, PT-141 does not significantly affect skin pigmentation, which was a primary characteristic of Melanotan II. This targeted action makes PT-141 distinct and specifically effective for its intended medical uses.

Beyond treating HSDD in women, PT-141’s scope extends to potential applications in erectile dysfunction (ED) and other sexual dysfunctions. Acting on melanocortin receptors, which are linked to sexual desire and appetite, PT-141 after subcutaneous injection reaches peak levels in about an hour, offering almost immediate effects on male sexual desire.

Clinical trials have highlighted PT-141’s benefits, especially for treating ED in men who don’t respond to sildenafil (Viagra). Studies demonstrated significant increases in erection duration and erectile response, indicating its effectiveness. Moreover, PT-141’s activation of presynaptic MC4Rs increases dopamine release, beneficial in treating HSDD in women. Research showed that women experienced more sexually satisfying events and reduced distress related to intercourse.

PT-141’s role isn’t limited to HSDD or ED; it has broader implications for general sexual dysfunction treatment. It has shown effectiveness in triggering sexual desire irrespective of the initial sexual stimulation, suggesting a versatile potential in addressing various sexual desire disorders.

Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction

PT-141: a melanocortin agonist for the treatment of sexual dysfunction